Quecitinib
Quecitinib (QY201) is an orally active JAK1/TYK2 dual inhibitor. Quecitinib is also a substrate of cytochrome P450 3A and is mainly metabolized to mono-oxide and glucuronidation products. Quecitinib has favorable pharmacokinetic properties as well as safety. Quecitinib can be used in the research of atopic dermatitis and other autoimmune diseases[1].
Product Specifications
CAS Number
2416858-84-7
Product Name Alternative
QY201
UNSPSC
12352005
Target
Cytochrome P450; JAK
Related Pathways
Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Inflammation/Immunology
Smiles
O[C@H](C)C1=NC2=CN=C(NC=C3)C3=C2N1N4CCC(CC#N)CC4
Molecular Formula
C17H20N6O
Molecular Weight
324.38
References & Citations
[1]Wang JY, et al. The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects. J Clin Pharmacol. 2025 May 27.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
JAK1; Tyk2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0665402 1.0 µg DNA
EIF2AK4 sgRNA CRISPR Lentivector (Human) (Target 1)
Sign In for Pricing
View Details 
H1865-05B-ML490 100 µL
Hemopexin (HPX, HX, Beta-1B-glycoprotein, FLJ56652, Hemo) (MaxLight 490) discontinued
Sign In for Pricing
View Details 